Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
Background Leukemia represents about 5% of all human cancers. Despite advances in therapeutics, a substantial number of patients succumb to the disease. Several subtypes of leukemia are inherently more resistant to treatment despite intensive chemotherapy or targeted therapy.Methods Here we describe...
Main Authors: | Brian Alexander, Lajos Pusztai, David L Rimm, Priti Hegde, Mariya Rozenblit, Richard Huang, Natalie Danziger, Shakti Ramkissoon, Kim Blenman, Jeffrey S Ross |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e001626.full |
Similar Items
-
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
by: Brian Alexander, et al.
Published: (2020-07-01) -
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
by: Daniele Caracciolo, et al.
Published: (2021-02-01) -
Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
by: Jose-Maria Ribera, et al.
Published: (2020-05-01) -
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
by: Jim Middelburg, et al.
Published: (2021-01-01) -
Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
by: Jason Manro, et al.
Published: (2021-07-01)